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Background: Control of human schistosomiasis remains a longstanding issue on the agenda of the Egyptian Ministry
of Health and Population (MOHP). Substantial impact on morbidity and prevalence of S. mansoni was widely reported
after the National Schistosomiasis Control Program (NSCP) extended selective treatment with praziquantel (PZQ)
to the Nile Delta in 1992 and upgrading this approach to mass drug administration (MDA) in 1997. Disease elimination,
however, eludes NSCP as the micro-level includes many high-risk foci that sustain transmission, which has not been
subjected to investigation.
Methods: The study included five high-risk Nile Delta villages situated in the Kafr El-Sheikh Governorate. The total
sample size amounted to 2382 individuals of both sexes and all ages. Diagnosis was based on four Kato-Katz
slides from two consecutive stool samples. Data were investigated using SPSS, comparing proportions with the
Chi square test and means with the Student t test, while strength of the associations were subjected to Odds
Ratio (OR) analysis.
Results: The overall prevalence of schistosomiasis in the study area was found to be 29 %, while the mean
geometric mean egg count (GMEC) was low (66.78 ± 4.4) indicating low intensity of infection. The mean village
prevalence rates ranged from 16.5 % to 49.5 % and the GMECs from 35.2 to 86.2 eggs per gram (EPG) of stool.
The difference of prevalence between villages was statistically significant at P < 0.05, and the prevalence was
significantly higher among males than among females, P < 0.05, OR =1.4 and 95 % CI (1.16-1.60). Infection peaked
in the next youngest age group (5-≤ 10 years of age) at an average prevalence of 50.8 % with the GMEC reaching 209
EPG of stool in the village with the highest prevalence. The average prevalence and GMEC among children <5 years
were 20.6 % and 92.7 EPG, respectively.
Conclusion: Transmission of S mansoni in high-risk areas in the Nile Delta remains uninterrupted calling for improved,
more comprehensive control strategies. Further investigations are needed to find out whether these results are due to
inefficacy of PZQ, surviving immature worms or drug resistance.
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The signing on 31 January 2012 of the London Declar-
ation by international politicians, heads of pharmaceutical
businesses and health-related, non-governmental organi-
zations (NGOs) represents a breakthrough in the fight
against the world’s neglected tropical diseases (NTDs) [1].
This commitment, based on a plan presented by the* Correspondence: elmorshedyh@hotmail.com
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creativecommons.org/publicdomain/zero/1.0/World Health Organization, offers hope that as many as
10 diseases, among them schistosomiasis, can be con-
trolled or eliminated as early as by the end of the current
decade [2].
Schistosomiasis is caused by a long-standing infection
with trematode worms of the genus Schistosoma. Humans
get infected during water contact through the release of
the infectious schistosome cercarial stage from the par-
asite’s intermediate snail host. The cerariae grow into
adult worms, which excrete a large number of eggs that
will eventually infect the snail when hatched in wateress article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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alternatively S. japonicum) or urine S. haematobium
(additional species exist but are uncommon). Transmis-
sion is sustained by lack of clean water and sanitation,
which explains why this is a disease of poverty [3]. The
sequelae of immune-mediated responses to schisto-
some eggs stranded in the human host varies according
to schistosome species. Untreated, the disease eventu-
ally produces fibrosis and obstructive manifestations
due to damage of the liver (in S. mansoni infections) or
the bladder (in S. haematobium infections) [4].
Human schistosomiasis is endemic at variable rates in
77 countries in tropical and subtropical regions of the
world, where the most recent estimates suggest that
more than 250 million people are infected resulting in a
global burden of 3.3 million disability-adjusted life years
(DALYs) [5, 6]. Various drugs and other measures have
been used to control schistosomiasis. However, shortly
after its discovery in the1970s [7], and follow-up clinical
trials [8], praziquantel (PZQ) replaced all other anti-
schistosomal drugs and is now the corner stone of schisto-
somiasis control programmes the world over. In the late
1990s, treatment strategies shifted from selective treat-
ment to mass drug administration (MDA) that means
treatment of all individuals living in endemic areas regard-
less of infection status [9].
Approximately, 12.7 million infected individuals are
clustered in the Middle East and North Africa (MENA) re-
gion and Egypt’s share of the burden is about 7.2 million
[10]. Both S. mansoni and S. haematobium species are
represented with the former species currently increasing
in importance and now dominating in the Nile Delta [11].
S. mansoni existed only sparsely along the Nile previously
and did not become common there until the 20th century,
a change ascribed to the ability of the S. mansoni snail
host Biomphalaria to survive in the less oxygenated water
resulting from intensified irrigation practices [12, 13]
followed by the Aswan High Dam construction [14]. The
replacement of S. haematobium with S. mansoni in the
Nile Delta was almost complete already 15 years ago [15],
and it is today unusual to find cases of urinary schistosom-
iasis in this part of Egypt. Several studies have docu-
mented this transformation and the appearance of new
foci favoring transmission of S. mansoni [16–19].
Regular control of schistosomiasis has been on the
agenda of the Egyptian Ministry of Health and Population
(MOHP) since 1922. Activities were strongly upgraded in
1976 through the organization of the National Schisto-
somiasis Control Project (NSCP), which started control
measures in the most endemic areas in Upper and Middle
Egypt. In 1992, activities were extended to all endemic
areas including the Nile Delta and in 1997, following
WHO’s recommendation, MDA was instituted throughout
the country [20]. The impact was rapid and substantialwith S. haematobium prevalence in Middle and Upper
Egypt falling from an average 29.3 % in 1977 to less than
3 % by the end of the 1990s [20, 21] followed by an even
lower rate for S. mansoni (1.5 % average prevalence) in the
Nile Delta by 2006 [22]. However, the long-term results
were not as positive everywhere. Baseline data collected
for a study before the first NSCP intervention in 1992
showed an average prevalence of 39.3 % of schistosomiasis
mansoni with an intensity of infection as measured by the
geometric mean egg count (GMEC) of 72.9 eggs per gram
(EPG) in Kafr El-Sheikh, a governorate in the northern
part of the Nile Delta [19, 23]. In 1993, after a period of
active case finding and selective chemotherapy of infected
individuals for two successive years, a significant drop in
prevalence and intensity of infection based on single stool
examinations using the Kato-Katz method was initially
achieved, both in high- and low-risk areas [23, 24]. How-
ever, in spite of the ongoing control activities this trend
was not sustained. Although prevalence rates and GMECs
remained below the baseline data, an upward trend was
observed in high-prevalence villages in 1997 [24, 25].
In view of more than 20 years of continuous treatment
with PZQ in the Nile Delta with elimination of morbidity
but stalling prevalence reduction, it was felt necessary to
revisit the situation and investigate the recent outcome of
long-term impact of MDA in a sub-regional, endemic
high-risk area.
Methods
As per the Egyptian MOHP control strategy of human
schistosomiasis, and in accordance with the WHO’s rec-
ommendations [20], PZQ MDA was instituted in 1997.
The rational was to scale up the application of MDA aim-
ing to control transmission rather than morbidity. PZQ
MDA is recommended if the prevalence of schistosomiasis
exceeds 3 % compared to 20 % according to the WHO
recommendations [11, 20–22]. Prevalence data are based
on annual screening of school children carried out by the
local Rural Health Units’ teams and further confirmed by
examining a random sample of all ages carried out by in-
dependent sentinel mobile teams assigned by the regional
health districts. Accordingly, PZQ MDA was offered to all
individuals 6 years and above. In 2011, all inhabitants of
the villages included in our study received PZQ in a single
oral dose of 40 mg/kg couple of months before the incep-
tion of the study. Before 2011, review of the official reports
of endemic disease departments of health directories both
in the Metobas District and in the Kafr El-Sheikh Gover-
norate by the authors revealed that these villages were
subjected to PZQ MDA annually since 2007.
Study site and population
In 2011, after a period of large-scale PZQ treatment carried
out by the MOHP in the Nile Delta, a cross-sectional study
Elmorshedy et al. Parasites & Vectors  (2015) 8:372 Page 3 of 8on schistosomiasis prevalence was undertaken in the Al-
Gezeera Al khadra and Arab Al Mahdar villages, including
the three small villages/ezbas of Al Ouidat, Abou Zeid,
and Abou Farag, Metobas District of the Kafr El-Sheikh
Governorate (Fig. 1). These villages were selected for
the study because of their continued high prevalence of
schistosomiasis mansoni. All the villages are situated in
the northern part of the Nile Delta bounded by Rosetta
branch of the Nile River in the West and the Mediter-
ranean Sea in the North. The location of these villages
at the far north part of the Rosetta branch (i.e., end of
the stream) provides flourishing breeding habitat of
the snail intermediate host of S. mansoni because of
the slow water currents and the abundant vegetation
in canals and drains. Of note, human water contact is
intense in these villages since fishing and rice cultiva-
tion are the occupations of the majority of people. Fur-
thermore, the inhabitants of these villages depend
partly on public tap water, whereas they still use canal
water intensively for domestic activities. Sanitary sewage
disposal is also lacking.Fig. 1 The districts of Kafr El-Sheik Governorate in the Northern Nile DeltaApproach
Schsistosomiasis is a seasonal disease, where most infec-
tions are acquired during the hot months of summer. The
field work of this study was conducted in 2011 during the
period from April through June where disease transmis-
sion occurs at an appreciable level. We first conducted a
house-to-house census survey inviting all age groups to
participate in the study. The number of houses included
in the study varied: 37 in Abou Farag, 38 in Al Ouidat, 56
in Abou Zeid, 66 in Arab Al Mahdarand 74 in Al Gezeera
Al khadra. The total number of participants in the study
amounted to 2382 individuals. The distribution of study
subjects per village was proportional to the number of
houses. All the households provided demographic infor-
mation, such as age and sex, that was collected and orga-
nized by trained data collectors.
Diagnosis
All participants and guardians of young children were
requested to provide two stool samples in two consecu-
tive days, collected at the same time each day. These
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technique [26]. Briefly, two slides each of 41.7 mg of
stool were prepared from each sample and day. The egg
counts of the four slides were averaged and the outcome
used for the analysis. To insure validity and reliability of
the parasitological data, 10 % of randomly selected slides
were re-examined and the EPG recounted. In addition,
any slide with only one egg was also rechecked by an ex-
perienced parasitologist.
Statistical analysis
Data were analyzed using SPSS, version 20.0 (IBM, New
York, NY, USA). All EPG values were transformed into
log 10 of the EPG +1 to allow for the zero counts and
the GMEC was computed as the anti-log 10 of the mean
of the log10 egg count. This was used because in areas
where repeated therapy interventions have taken place,
the distribution of the intensity of infection measured by
EPG has the tendency to become right-skewed, i.e., in
the majority of cases, there are only a few or no parasites
left after treatment, while a few individuals showed rela-
tively large parasite burdens, a tendency best described
by considering their GMEC. We used odds ratio (OR) to
express the strength of association between dichotomous
variables and the Pearson’s Chi square test to compare
between proportions. The independent sample t-test was
used to compare the intensity of infection as measured
by GMEC with regard to villages and age categories. All
tests were two-sided with the p = 0.05 level for statistical
significance accepted as the cut-off value.
Ethical approval
The study was reviewed and approved by the Ethical re-
view Board, High Institute of Public Health, Alexandria
University, Egypt.
Results
Out of the 2382 individuals interviewed, 1493 (including
both sexes and all ages) provided stool samples. Table 1
demonstrates the prevalence of S. mansoni infection ac-
cording to village and gender. The overall prevalenceTable 1 Prevalence of Schistosomamansoni infection with respect to
Area (Ezba) Total population
Number examined Number positive % posit
Arab Al Mahdar 377 173 45.9
Al Ouidat O260 84 32.3
Abou Zeid 204 49 24
Al Gezeera Al Khadra 415 88 21.2
Abou Farag 237 39 16.5
Total 1493 433 29b
aStatistically significant at p <0.05
bDifferences between the village prevalence rates were statistically significant (X2 =was 29 % with the highest value in Arab Al Mahdar
(45.9 %). With the prevalence rates for the other villages
ranging from 16.5 % to 32.3 %, it is evident that all the
study villages must be considered as having moderate
schistosomiasis risk. The difference in prevalence between
villages was statistically significant at the p < 0.05 level.
With respect to gender, the overall prevalence of infection
was significantly higher among males than among females:
P < 0.05, OR =1.4 and 95 % CI (1.164-1.6). Although the
prevalence of infection was higher among males than
among females in all villages, the difference was only stat-
ically significant in Arab Al Mahdar, Al Ouidat and Abou
Zeid, the three villages with the highest prevalence values.
When people are divided into 10-year ranges according
to age, it can be seen that the cases in all villages were
clustered in the range between 5 and 20 years of age,
followed by a considerable reduction of cases among older
people (Fig. 2). However, an increased prevalence for 30-
40 and 40-50 year olds were also found in Abou Zeid and
Arab Al Mahdar, respectively.
In Table 2, the infection pattern was analyzed from the
viewpoint of three age categories: <5, 5 - ≤10 and >10. It
is again obvious that the burden of infection is the high-
est among young people, in particular in the group aged
5 - ≤10, where there was about a two-fold increase in
prevalence as compared to those in the >10 age group
(OR = 1.9, 95 % CI(1.61-2.62)) and 2.5-fold compared to
children below 5 (OR = 2.5, 95 % CI (1.79 – 3.47)). It is
notable that across the villages, the difference in preva-
lence was not statistically significant P > 0.05 for the first
two age categories (those below10 years of age).
Table 3 and Fig. 3 demonstrate that the intensity of in-
fection (GMCE) increased as prevalence increased. The
overall GMEC was 66.7 ± 4.11, while it was 92.7 and
95.6 for children <5 and 5 - ≤10, respectively. In com-
parison, GMEC was only 57.3 in the group >10 years of
age. Intensity of infection was significantly higher among
children ≤ 10 years of age,
P = <0.05. This relation was more prominent in the vil-
lage with the highest prevalence, yet it was maintained
in nearly all the communities.village and gender
Males Females
ive Number positive % positive Number positive % positive
93 51.4 80 40.8a
47 38.5 37 26.8a
32 29.9 17 17.5a
42 23.1 46 19.7
20 20.2 19 13.8
234 33.9 199 24.8








<5 5- 10- 20- 30- 40+
Arab Al Mahdar Al Ouidat Abou Zeid Al Gezeera Al Khadra Abou Farag
Fig. 2 S. mansoni prevalence with regard to age and village
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Schistosomiasis control based on MDA using PZQ in
Egypt has been exceptionally successful, both with re-
gard to morbidity and to prevalence [20, 22]. However,
these reports are country- or region-wide, thus neglect-
ing the potential impact due to focal high-risk areas,
which become masked by results from larger areas in
other parts of the country with currently negligible
prevalence rates. The presence of local situations, such
as Kafr El-Sheikh, where the probability of immature
infection is high due to numerous patches with in-
creased levels of transmission, calls for modification of
local control strategies during the implementation phaseTable 2 Prevalence of Schistosomamansoni infection according
to age group









64 26.6 55 56.4 256 48.3
Al Ouidat 44 20.5 38 57.9 178 29.9
Abou Zeid 30 13.3 38 31.6 136 24.3
Al Gezeera
Al Khadra
5 0.0 28 53.6 381 19.2
Abou Farag 24 16.7 32 53.1 181 9.9
Total 167 20.4 191 50.8 1135 26.6
X2 — 3.912 —— 7.219 – 100.048
P 0.074 0.272 0.00of chemotherapy taking into account the fact that PZQ is
ineffective against the schistosomula and immature worms
[27]. Possible modifications include temporally closer
PZQ rounds or use of drug combinations including a
complementary artemether derivative [28].
Comparison of the results of the present study with
those from the time just before the initial active inter-
vention (the baseline data) [29], clearly demonstrates
that the ongoing chemotherapy programme remains ef-
fective with respect to morbidity. Prevalence previously
peaked in adolescents (16-20 years of age), while the
GMEC was lower, probably thanks to long-term avail-
ability of PZQ [29]. The low prevalence and low inten-
sity of infection among older age groups versus an
almost 2.5-fold increase in prevalence and a fairly high
GMEC in children below 10 seen in the present study
can be attributed to partial immunity [30]. A decrease in
prevalence and intensity of infection among older indi-
viduals would then be expected, yet this decrease may
not reflect an actual decrease in the prevailing strength
of transmission. In reality, it is possible that local trans-
mission could actually be on the increase since preva-
lence and GMEC in children were higher in our study
than reported previously [31]. However, although the
moderate GMEC rates seen here (Table 3) indicate that
ongoing interventions are successful with regard to mor-
bidity, Table 2 and Fig. 2 reveal that prevalence rates
among children are unacceptably high reflecting contin-
ued high levels of transmission. Thus, the main reason
for the failure of elimination of schistosomiasis locally
Table 3 Intensity of Schistosomamansoni infection according to age group
Age groupVillage
<5 5 - ≤ 10 >10
Positive GMECa Positive GMECa Positive GMECa
Arab Al Mahdar 17 128.9 ± 4.9 31 209.7 ± 5.1 125 63.1 ± 3.4
Al Ouidat 9 42.5 ± 3.2 22 90.01 ± 5.2 53 63.7 ± 4.3
Abou Zeid 4 109.4 ± 8.2 12 52 ± 3.5 33 67.2 ± 3.0
Al Gezeera Al Khadra 0 – 15 99.80 ± 6.2 73 44.0 ± 3.5
Abou Farag 4 111.6 ± 3.9 17 36.60 ± 3.4 18 29.4 ± 3.6
Total 34 92.7 ± 4.7 97 95.6 ± 5.26 302 57.3 ± 3.62
aMean geometric mean egg count ± SD
GMEC was significantly higher among children ≤ 10 years,P = <0.05
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(MDA with PZQ) to stop transmission, even when regu-
larly repeated.
Following two rounds of PZQ selective treatment in
Kafr El-Sheikh, the prevalence rates of the high-risk vil-
lages approached that of the low-risk ones: 20.5 % and
19.5 %, respectively, as compared to 44.9 % and 33.5 %,
reported for them at the baseline [31]. In addition, two
previous studies in this governorate reported lower
prevalence rates (29 % and 45 %, respectively) among
primary school children than our present study. In both
these studies, the GMEC values were also low (62 and
58, respectively) [28, 32]. Despite the fact that both these
studies report good effect on morbidity with prevalenceFig. 3 Geometric means of egg counts among children 5- < 10 years versudata at a lower boundary than our study, there was no
influence on transmission.
The results from a majority of the study villages cor-
roborate the well-known picture of peak prevalence
and intensity of infection among 5-10 years old young
children (Figs 2 and 3, Tables 2 and 3) followed by sig-
nificantly lower values in adolescence and old age. In
Arab Al Mahdar and Abou Zeid, however, there was no
such marked reduction of prevalence after the initial
peak. Although both these villages showed a similar de-
velopment over the age groups, the former showed
considerably higher prevalence rates for all age groups
compared to the latter. On the other hand, the pattern
of schistosomiasis prevalence among children less thans total population with regard to village
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in all the villages studied with no statistically significant
inter-village difference (Tables 1 and 2). Observed vari-
ations in the overall prevalence between the villages are
therefore exclusively contributed by older individuals,
particularly in Arab Al Mahdar and Abou Zeid, which
emphasizes failure of instituted control measures. How-
ever, this should be seen against the background of the
overall high prevalence that would have been lower,
had transmission been less pronounced.
The potential underlying factors for the observed re-
bound in infections in spite of repeated PZQ treatment
schedules are several. Concerns regarding the emergence
of schistosome strains with reduced susceptibility or tol-
erance to PZQ has been expressed [33]. The argument,
whether this represents a selection of resistant worm
populations under drug pressure or incomplete cure
[34] is still an open question. However, extensive appli-
cation of PZQ for almost 40 years in Upper and Middle
Egypt and for more than 20 years in the Nile Delta
should have imposed strong selection of the parasite
populations in all of Egypt. There are reasons to believe
that continuous drug pressure for this long should have
had an effect by now and there is evidence pointing in
this direction, e.g., microsatellite analysis has shown
presence of a single S. mansoni genotype in naturally in-
fected intermediate host Biomphalaria alexandrina snails
collected from water channels in the Nile Delta [35].
Moreover, reduction in genetic diversity of a Tanzanian
schistosome population was reported after only one round
of treatment [36]. Naturally selected drug resistance has
also been reported for oxamniquine in Brazil [37].
Apart from the role of stage-selective drug action, as
that exerted by PZQ, cure rates do not reach 100 % but ra-
ther range from 80 % to 90 % as noted in Kafr El-Sheik
[32]. There are also other factors having to do with socio-
cultural and environmental issues as well as the quality of
health service operations at the peripheral level. Potential
complacency with regard to repeated chemotherapy and
follow-up testing is yet another problem that needs to
be investigated. The combined effect of all these factors
is difficult to estimate, but there will be no let-up in
transmission as long as parasite eggs continue to be ex-
creted directly into the field.
Whether the observed high prevalence rates among chil-
dren in our study is due to strong transmission resulting
in reinfection, development of surviving schistosomula
into adult worms or reduced susceptibility of adult worms
to PZQ should be considered in addition to the ongoing
regime, especially for the high-risk areas. Combining
chemotherapy of PZQ with, for example, artemether that
exclusively affects the immature worm should contribute
to a better cure rate by covering the full spectrum of
the parasite development in the definitive host. Suchcombination therapies have been used in Kafr El-Sheikh
with impressive results [28]. Following one round of
combined treatment, prevalence was reduced from
30 % to 6.8 % and incidence of new infections fell to
2.7 %. Still, elimination based on chemotherapy alone,
given the presence of remote high-risk areas, will be
difficult to achieve, so other measures as socio-cultural
development, environmental sanitation and functioning
public health services are necessary adjuncts.
Conclusion
 PZQ is the solution to morbidity in endemic areas
but only if regularly repeated. Continued
transmission after PZQ treatment is well-known,
but the long-term consequences of this fact have
not been given appropriate attention.
 Focal transmission of S mansoni in the Nile Delta
remains uninterrupted calling for improved, more
comprehensive control strategies. PZQ treatment
should remain the cornerstone of control, but
elimination strategies need additional input, e.g.,
snail control,complimentary drugs, upgraded
sanitation and/or improved public health service
capable to deal with potential complacency with
regard to repeated chemotherapy rounds.
 As long as some patients remain infected, eggs will
continue to be excreted into the field assuring
continued transmission. The observed rebound of
schistosomiasis in spite of long-term, repeated PZQ
treatment in the Nile Delta is therefore cause of
grave concern. Further investigations are needed to
find out the reason(s) for the current failure of
up-to-date control strategies in the Nile Delta
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